Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD+ levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD+) levels to prevent dementia. We tested if the administration of the precursor of NAD+, nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD+ levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD+, activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160 · cited 1×
“SIRT1 is a major regulator of mitochondrial biogenesis and metabolism; it activates PGC-1α and in turn promotes mitochondrial biogenesis [27,28,43].”
BackgroundWest, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994 · cited 4×
“The extent of the CA1 layer is defined by the stratum pyramidale on one side and by perforant path fibers on the other [41,42].”
BackgroundMethodInfluentialModulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750 · cited 1×
“SIRT1 is a deacetylase enzyme that acetylates transcription factors; prominent amongst these transcription factors are PGC-1α [27–29], FoxO family members [30], NF-κB [31], and p53 [32].”
BackgroundDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648 · cited 1×
“The Km for NAD+ of some sirtuins is high (SIRT1 ~100 μM); these enzymes can act as NAD+ sensors (cellular NAD+ is 200–500 μM) when there are physiological and pathological changes in NAD+ levels, translating metabolic cues into enzymatic and transcriptional adaptations [26].”
BackgroundYoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.014 · Cited by 1,340
Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α
Gerhart‐Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S., Mostoslavsky, R., Alt, F. W., Wu, Z., & Puigserver, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601633 · Cited by 1,294 · cited 1×
“SIRT1 is a major regulator of mitochondrial biogenesis and metabolism; it activates PGC-1α and in turn promotes mitochondrial biogenesis [27,28,43].”
BackgroundCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 3×
“Therapeutic interventions with key NAD+ intermediates, such as NMN and nicotinamide riboside (NR), which can replenish cellular NAD+ levels, have drawn significant attention in the field of aging, diabetes, obesity, and metabolic syndrome [16,18,24,25].”
BackgroundNAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
Yoshino, J., Baur, J. A., & Imai, S.-I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.002 · Cited by 1,061 · cited 5×
“NMN is also synthesized from NR via a nicotinamide riboside kinase (NRK)-mediated phosphorylation reaction [18,49,51].”
BackgroundInfluentialMills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, M. E., Apte, R. S., Uchida, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.013 · Cited by 930 · cited 1×
“Long-term (1 year) oral administration of NMN (up to 300 mg/kg) is not associated with any obvious adverse effects in normal wildtype C57BL/6 mice [48], and recent clinical studies show that NMN is well tolerated in humans [54].”
Background
Research works printed but not linked: 60
- Grunblatt, 2011, The link between iron, metabolic syndrome, and Alzheimer’s disease, J. Neural Transm., 118, 371, 10.1007/s00702-010-0426-3 · DOI
- Ma, 2019, Neuroprotective effect of resveratrol via activation of Sirt1 signaling in a rat model of combined diabetes and Alzheimer’s disease, Front. Neurosci., 13, 1400, 10.3389/fnins.2019.01400 · DOI
- Zhou, 2018, Mitochondrial perturbation contributing to Cognitive Decline in Streptozotocin-Induced Type 1 Diabetic Rats, Cell Physiol. Biochem., 46, 1668, 10.1159/000489243 · doi:10.1159/000489243
- Cardoso, 2010, Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia, Biochim. Biophys. Acta, 1802, 942, 10.1016/j.bbadis.2010.07.001 · DOI
- Muriach, 2014, Diabetes and the brain: Oxidative stress, inflammation, and autophagy, Oxid. Med. Cell Longev., 2014, 102158, 10.1155/2014/102158 · DOI · Paper page
- Balonga, 2013, Mitochondrial dysfunction in brain cortex mitochondria of STZ-diabetic rats: Effect of l-Arginine, Neurochem. Res., 38, 2570, 10.1007/s11064-013-1172-3 · DOI
- Salceda, 2018, Mitochondrial activity in different regions of the brain at the onset of streptozotocin-induced diabetes in rats, Mol. Biol. Rep., 45, 871, 10.1007/s11033-018-4233-5 · DOI
- Butterfield, 2014, Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain, Biochim. Biophys. Acta, 1842, 1693, 10.1016/j.bbadis.2014.06.010 · DOI · Paper page
- Zhang, 2015, Region-specific cerebral metabolic alterations in streptozotocin-induced type 1 diabetic rats: An in vivo proton magnetic resonance spectroscopy study, J. Cereb. Blood Flow Metab., 35, 1738, 10.1038/jcbfm.2015.111 · DOI
- Jin, 2016, Effects of oxidative stress on hyperglycaemia-induced brain malformations in a diabetes mouse model, Exp. Cell Res., 347, 201, 10.1016/j.yexcr.2016.08.002 · DOI
- Yang, 2013, Long-term streptozotocin-induced diabetes in rats leads to severe damage of brain blood vessels and neurons via enhanced oxidative stress, Mol. Med. Rep., 7, 431, 10.3892/mmr.2012.1227 · DOI
- Zhao, 2016, Changes in neurons and synapses in hippocampus of streptozotocin-induced type 1 diabetes rats: A stereological investigation, Anat. Rec., 299, 1174, 10.1002/ar.23344 · DOI
- Belenky, 2007, NAD+ metabolism in health and disease, Trends Biochem. Sci., 32, 12, 10.1016/j.tibs.2006.11.006 · DOI · Paper page
- Osterloh, 2012, dSarm/Sarm1 is required for activation of an injury-induced axon death pathway, Science, 337, 481, 10.1126/science.1223899 · DOI · Paper page
- Geisler, 2016, Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice, Brain, 139, 3092, 10.1093/brain/aww251 · DOI · Paper page
- Turkiew, 2017, Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy, J. Peripher. Nerv. Syst., 22, 162, 10.1111/jns.12219 · DOI · Paper page
- Sasaki, 2019, Metabolic aspects of neuronal degeneration: From a NAD(+) point of view, Neurosci. Res., 139, 9, 10.1016/j.neures.2018.07.001 · DOI
- Bogan, 2008, Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition, Annu. Rev. Nutr., 28, 115, 10.1146/annurev.nutr.28.061807.155443 · DOI · Paper page
- Rodgers, 2008, Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways, FEBS Lett., 582, 46, 10.1016/j.febslet.2007.11.034 · DOI · Paper page
- Dominy, 2010, Nutrient-dependent regulation of PGC-1alpha’s acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5, Biochim. Biophys. Acta, 1804, 1676, 10.1016/j.bbapap.2009.11.023 · DOI · Paper page
- Brunet, 2004, Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase, Science, 303, 2011, 10.1126/science.1094637 · DOI · Paper page
- Vaziri, 2001, hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase, Cell, 107, 149, 10.1016/S0092-8674(01)00527-X · DOI · Paper page
- Tanner, 2000, Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose, Proc. Natl. Acad. Sci. USA, 97, 14178, 10.1073/pnas.250422697 · DOI · Paper page
- Jackson, 2003, Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases, J. Biol. Chem., 278, 50985, 10.1074/jbc.M306552200 · DOI · Paper page
- Chalkiadaki, 2012, Sirtuins mediate mammalian metabolic responses to nutrient availability, Nat. Rev. Endocrinol., 8, 287, 10.1038/nrendo.2011.225 · DOI · Paper page
- Lagouge, 2006, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, 127, 1109, 10.1016/j.cell.2006.11.013 · DOI · Paper page
- Choi, 2014, Brain diabetic neurodegeneration segregates with low intrinsic aerobic capacity, Ann. Clin. Transl. Neurol., 1, 589, 10.1002/acn3.86 · DOI · Paper page
- Wiegers, 2019, Elevated brain glutamate levels in type 1 diabetes: Correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status, Diabetologia, 62, 1065, 10.1007/s00125-019-4862-9 · DOI
- Zhao, 2018, Metabolomic analysis identifies lactate as an important pathogenic factor in diabetes-associated cognitive decline rats, Mol. Cell Proteomics, 17, 2335, 10.1074/mcp.RA118.000690 · DOI
- Golub, 2015, Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration, Front. Aging Neurosci., 7, 196, 10.3389/fnagi.2015.00196 · DOI
- Li, 2013, Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3, Mol. Neurobiol., 48, 490, 10.1007/s12035-013-8437-3 · DOI
- Chandrasekaran, 2019, Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy, Brain, 142, 3737, 10.1093/brain/awz324 · DOI
- Smith, 2012, Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes, Brain, 135, 1751, 10.1093/brain/aws097 · DOI · Paper page
- Klimova, 2020, NAD(+) precursor modulates post-ischemic mitochondrial fragmentation and reactive oxygen species generation via SIRT3 dependent mechanisms, Exp. Neurol., 325, 113144, 10.1016/j.expneurol.2019.113144 · DOI
- Lin, 2016, NAMPT-mediated NAD(+) biosynthesis is essential for vision in mice, Cell Rep., 17, 69, 10.1016/j.celrep.2016.08.073 · DOI · Paper page
- Klimova, 2019, Multi-targeted effect of nicotinamide mononucleotide on brain bioenergetic metabolism, Neurochem. Res., 44, 2280, 10.1007/s11064-019-02729-0 · DOI
- Long, A.N., Owens, K., Schlappal, A.E., Kristian, T., Fishman, P.S., and Schuh, R.A. (2015). Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol., 15. · DOI · Paper page
- Park, 2016, Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia, Neurobiol. Dis., 95, 102, 10.1016/j.nbd.2016.07.018 · DOI · Paper page
- Mittal, 2016, Shared links between type 2 diabetes mellitus and Alzheimer’s disease: A review, Diabetes Metab. Syndr., 10, S144, 10.1016/j.dsx.2016.01.021 · DOI
- Backes, 2016, Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning, Medicine, 95, e4803, 10.1097/MD.0000000000004803 · DOI
- Dugan, 1994, Excitotoxicity, free radicals, and cell membrane changes, Ann. Neurol., 35, S17, 10.1002/ana.410350707 · DOI · Paper page
- Alkadhi, 2019, Cellular and molecular differences between area CA1 and the dentate gyrus of the hippocampus, Mol. Neurobiol., 56, 6566, 10.1007/s12035-019-1541-2 · DOI
- Sherwin, 2003, Metabolic parameters of epilepsy: Adjuncts to established antiepileptic drug therapy, Neurochem. Res., 28, 353, 10.1023/A:1022433421761 · DOI
- Martinez, 2016, Metabolism of N-acetyl-L-aspartate: Its diagnostic and prognostic value, Rev. Neurol., 62, 361
- Moffett, 2013, N-Acetylaspartate reductions in brain injury: Impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation, Front. Neuroenergetics, 5, 11, 10.3389/fnene.2013.00011 · DOI · Paper page
- Geddes, 2003, Susceptibility of hippocampal neurons to mechanically induced injury, Exp. Neurol., 184, 420, 10.1016/S0014-4886(03)00254-1 · DOI
- Lin, 1998, Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: Microglial, astrocytic and endothelial alterations, Acta Neuropathol., 96, 610, 10.1007/s004010050942 · DOI
- Eichenbaum, 2000, Hippocampus: Mapping or memory?, Curr. Biol., 10, R785, 10.1016/S0960-9822(00)00763-6 · DOI · Paper page
- Ho, 2013, Effects of diabetes on hippocampal neurogenesis: Links to cognition and depression, Neurosci. Biobehav. Rev., 37, 1346, 10.1016/j.neubiorev.2013.03.010 · DOI · Paper page
- Trudeau, 2004, Hippocampal synaptic plasticity and glutamate receptor regulation: Influences of diabetes mellitus, Eur. J. Pharmacol., 490, 177, 10.1016/j.ejphar.2004.02.055 · DOI · Paper page
- Sansbury, 2011, Bioenergetic function in cardiovascular cells: The importance of the reserve capacity and its biological regulation, Chem. Biol. Interact., 191, 288, 10.1016/j.cbi.2010.12.002 · DOI · Paper page
- Xu, 2018, Brain SIRT1 mediates metabolic homeostasis and neuroprotection, Front. Endocrinol., 9, 702, 10.3389/fendo.2018.00702 · DOI
- Sun, 2017, The E3 ubiquitin ligase NEDD4 is an LC3-interactive protein and regulates autophagy, Autophagy, 13, 522, 10.1080/15548627.2016.1268301 · DOI
- Camera, 2016, Learning, memory and long-term potentiation are altered in Nedd4 heterozygous mice, Behav. Brain Res., 303, 176, 10.1016/j.bbr.2016.01.054 · DOI
- DiAntonio, 2010, Nedd4 branches out, Neuron, 65, 293, 10.1016/j.neuron.2010.01.028 · DOI
- Liang, 2014, Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS, Bioanalysis, 6, 1445, 10.4155/bio.14.8 · DOI
- Kristian, 2011, Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection, J. Neurosci. Res., 89, 1946, 10.1002/jnr.22626 · DOI · Paper page
- Owens, 2013, Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury, Transl. Stroke Res., 4, 618, 10.1007/s12975-013-0278-x · DOI
- Anjaneyulu, 2008, Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy, Exp. Neurol., 211, 469, 10.1016/j.expneurol.2008.02.011 · DOI
- Russell, 2008, Oxidative injury and neuropathy in diabetes and impaired glucose tolerance, Neurobiol. Dis., 30, 420, 10.1016/j.nbd.2008.02.013 · DOI
Cited by
Alegre, G. F. S., & Pastore, G. M. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00475-y · Cited by 101
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy
Coleman, M. P. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01297-6 · Cited by 33
“In connection with this, there is now a substantial literature and wider public discussion of therapy and prevention of neurological disorders using precursors of NAD, such as nicotinamide (Nam) and its riboside (NR) or mononucleotide (NMN) [114, 115, 116].”
BackgroundIdentification and Experimental Validation of Marker Genes between Diabetes and Alzheimer’s Disease
Huang, C., Wen, X., Xie, H., Hu, D., & Li, K. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8122532 · Cited by 15
“Studies have reported that the volume of the hippocampal CA1 region was significantly reduced in the streptozotocin-induced diabetic rats [48], accompanied by a decrease in the number of spinophi- lin-/neurabin II-positive cells; in addition, ultrastructural observations revealed widening of the…”
Metadata
- Authors
- Chandrasekaran, K., Choi, J., Arvas, M. I., Salimian, M., Singh, S., Xu, S., Gullapalli, R. P., Kristian, T., & Russell, J. W.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-26
- Volume
- 21
- Issue
- 11
- Pages
- 3756
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3028677469
- Cited by
- 81
- References
- 16
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK107007-01A1)
- Office of Research Development, Department of Veterans Affairs (101RX001030, BX000917 (T.K.))
- Atlantic Nutrition Obesity Research Center, grant P30, NIDDK, NIH (DK072488)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.